Search

Search results

1498 results found

Cytokines and growth factors in the developing intestine and during necrotizing enterocolitis.

Publication: Journal Article

MohanKumar, Krishnan, Kopperuncholan Namachivayam, Thao T B Ho, Benjamin A Torres, Robin K Ohls, and Akhil Maheshwari. 2017. “Cytokines and Growth Factors in the Developing Intestine and During Necrotizing Enterocolitis.”. Seminars in Perinatology 41 (1): 52-60.

News + Updates

Page

Powerful websites to share your science story: from team and research to publications and impact.

Rico served as a lab manager and biological scientist at the Ho lab where he investigated iron regulatory and absorption mechanisms in-vitro using premature intestinal epithelial cells and an enteroid model derived from premature infant tissue. Rico is currently attending medical school at Boonshoft...

Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Movement Disorders 1994;9:467-469.

Publication: Journal Article

Hauser, RA, and R Trehan. 1994. “Initial Experience With Electroconvulsive Therapy for Progressive Supranuclear Palsy. Movement Disorders 1994;9:467-469.”. Movement Disorders.

The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993;43:1704-1708.

Publication: Journal Article

Woodward, WR, CW Olanow, RM Beckner, RA Hauser, LL Gauger, JM Cedarbaum, and J Nutt. 1993. “The Effect of L-Dopa Infusions With and Without Phenylalanine Challenges in Parkinsonian Patients: Plasma and Ventricular CSF L-Dopa Levels and Clinical Responses. Neurology 1993;43:1704-1708.”. Neurology.

Effective Parkinson’s treatment. An update on strategy. Senior patient. 1990;2:26-31.

Publication: Journal Article

Hauser, RA, and CW Olanow. 1990. “Effective Parkinson’s Treatment. An Update on Strategy. Senior Patient. 1990;2:26-31.”. Senior Patient.

Tolcapone and hepatotoxic effects. Arch Neurol 2000:57; 263-267.

Publication: Journal Article

Olanow, CW, and Tasmar Advisory Panel. 2000. “Tolcapone and Hepatotoxic Effects. Arch Neurol 2000:57; 263-267.”. Arch Neurol.

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Movement Disorders 2000;15:485-489.

Publication: Journal Article

Hauser, RA, WC Koller, JP Hubble, T Malapira, K Busenbark, and WC Olanow. 2000. “Time Course of Loss of Clinical Benefit Following Withdrawal of Levodopa/Carbidopa and Bromocriptine in Early Parkinson’s Disease. Movement Disorders 2000;15:485-489.”. Movement Disorders.

Pramipexole-induced somnolence and episodes of daytime sleep. Movement Disorders 2000;15:658-663.

Publication: Journal Article

Hauser, RA, L Gauger, WM Anderson, and TA Zesiewicz. 2000. “Pramipexole-Induced Somnolence and Episodes of Daytime Sleep. Movement Disorders 2000;15:658-663.”. Movement Disorders.

Search

Search results

Cytokines and growth factors in the developing intestine and during necrotizing enterocolitis.

News + Updates

Past Members

Rico Carter

Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Movement Disorders 1994;9:467-469.

The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993;43:1704-1708.

Effective Parkinson’s treatment. An update on strategy. Senior patient. 1990;2:26-31.

Tolcapone and hepatotoxic effects. Arch Neurol 2000:57; 263-267.

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Movement Disorders 2000;15:485-489.

Pramipexole-induced somnolence and episodes of daytime sleep. Movement Disorders 2000;15:658-663.